Lupin rallies after receiving USFDA nod for arterial hypertension drug

24 Mar 2022 , 02:13 PM

Sildenafil is a market a generic equivalent of Revatio of Viatris Specialty LLC. Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension.

According to IQVIA, Sildenafil had estimated annual sales of $66 million in US in the month of December 2021.

Lupin said the product will be manufactured at its facility in Goa, India.

Lupin is a transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The companys consolidated net profit jumped 24.47% to Rs 545.52 crore on a 3.57% rise in total revenue from operations to Rs 4160.93 crore in Q3 FY22 over Q3 FY21.

Powered by Capital Market – Live News